DNLI
Price
$23.11
Change
-$0.31 (-1.32%)
Updated
Jul 24 closing price
Capitalization
3.67B
5 days until earnings call
Intraday BUY SELL Signals
SRPT
Price
$15.68
Change
-$0.20 (-1.26%)
Updated
Jul 24 closing price
Capitalization
1.65B
11 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNLI vs SRPT

DNLI vs SRPT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DNLI vs. SRPT commentary
Jul 26, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongBuy and SRPT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2026
Stock price -- (DNLI: $23.11 vs. SRPT: $15.68)
Brand notoriety: DNLI: Not notable vs. SRPT: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 41% vs. SRPT: 41%
Market capitalization -- DNLI: $3.67B vs. SRPT: $1.65B
DNLI [@Biotechnology] is valued at $3.67B. SRPT’s [@Biotechnology] market capitalization is $1.65B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileSRPT’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • SRPT’s FA Score: 0 green, 5 red.
According to our system of comparison, DNLI is a better buy in the long-term than SRPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while SRPT’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 4 bearish.
  • SRPT’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than SRPT.

Price Growth

DNLI (@Biotechnology) experienced а -0.77% price change this week, while SRPT (@Biotechnology) price change was -8.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.78%. For the same industry, the average monthly price growth was -3.76%, and the average quarterly price growth was +1901.89%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 30, 2026.

SRPT is expected to report earnings on Aug 05, 2026.

Industries' Descriptions

@Biotechnology (-4.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($3.67B) has a higher market cap than SRPT($1.65B). DNLI YTD gains are higher at: 39.976 vs. SRPT (-27.138). SRPT has higher annual earnings (EBITDA): 125M vs. DNLI (-531.76M). DNLI has more cash in the bank: 988M vs. SRPT (653M). DNLI has less debt than SRPT: DNLI (34.5M) vs SRPT (1.04B). SRPT has higher revenues than DNLI: SRPT (2.18B) vs DNLI (0).
DNLISRPTDNLI / SRPT
Capitalization3.67B1.65B222%
EBITDA-531.76M125M-425%
Gain YTD39.976-27.138-147%
P/E RatioN/A44.77-
Revenue02.18B-
Total Cash988M653M151%
Total Debt34.5M1.04B3%
FUNDAMENTALS RATINGS
DNLI vs SRPT: Fundamental Ratings
DNLI
SRPT
OUTLOOK RATING
1..100
7478
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9986
PRICE GROWTH RATING
1..100
4262
P/E GROWTH RATING
1..100
9976
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SRPT's Valuation (81) in the Biotechnology industry is in the same range as DNLI (92). This means that SRPT’s stock grew similarly to DNLI’s over the last 12 months.

SRPT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that SRPT’s stock grew similarly to DNLI’s over the last 12 months.

SRPT's SMR Rating (86) in the Biotechnology industry is in the same range as DNLI (99). This means that SRPT’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's Price Growth Rating (42) in the Biotechnology industry is in the same range as SRPT (62). This means that DNLI’s stock grew similarly to SRPT’s over the last 12 months.

SRPT's P/E Growth Rating (76) in the Biotechnology industry is in the same range as DNLI (99). This means that SRPT’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLISRPT
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 17 days ago
77%
Bullish Trend 17 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signal:
Gain/Loss:
SRPT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BYRE28.470.63
+2.25%
Principal Real Estate Active Opp ETF
PSP58.520.88
+1.53%
Invesco Global Listed Private Equity ETF
FEGE49.330.39
+0.80%
FIRST EAGLE GLOBAL EQUITY ETF
COYY17.68N/A
N/A
GraniteShares YieldBOOST COIN ETF
QLTA46.51-0.01
-0.01%
iShares Aaa - A Rated Corporate Bond ETF

SRPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SRPT has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if SRPT jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRPT
1D Price
Change %
SRPT100%
-1.26%
AXON - SRPT
43%
Loosely correlated
+2.12%
RCKT - SRPT
42%
Loosely correlated
-2.74%
DNLI - SRPT
42%
Loosely correlated
-1.32%
BCAX - SRPT
39%
Loosely correlated
-2.56%
REPL - SRPT
39%
Loosely correlated
-7.27%
More